You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

Claims for Patent: 10,369,219

✉ Email this page to a colleague

Summary for Patent: 10,369,219

Title:	Composition for enhancing induction of humoral immunity, and vaccine pharmaceutical composition
Abstract:	The present invention aims to provide a composition for promoting humoral immunity induction and a vaccine pharmaceutical composition that can be universally used for various antigens in inducing humoral immunity to antigens, contain a Th2 reaction promoter, and exerts a high humoral immunity inducing effect. The present invention relates to a vaccine pharmaceutical composition containing an antigen for humoral immunity induction and at least one Th2 reaction promoter.
Inventor(s):	Shishido; Takuya (Osaka, JP), Asari; Daisuke (Osaka, JP), Matsushita; Kyohei (Osaka, JP), Hori; Mitsuhiko (Osaka, JP)
Assignee:	NITTO DENKO CORPORATION (Osaka, JP)
Application Number:	15/501,271
Patent Claims:	1. A method for promoting humoral immunity induction in a subject in need thereof, comprising: administering to the subject an effective amount of a G protein-coupled receptor (GPCR) ligand that is at least one selected from an antagonist for a Gi-coupled GPCR and an antagonist for a Gq-coupled GPCR. 2. A method for promoting humoral immunity induction in a subject in need thereof, comprising: administering to the subject an effective amount of a pharmaceutical composition comprising: an antigen for humoral immunity induction; and a G protein-coupled receptor (GPCR) ligand that is at least one selected from an antagonist for a Gi-coupled GPCR and an antagonist for a Gq-coupled GPCR. 3. The method according to claim 1, wherein the antagonist is selected from the group consisting of an adrenergic receptor antagonist, a muscarinic receptor antagonist, a dopamine receptor antagonist, a histamine receptor antagonist, a serotonin receptor antagonist, a PAF receptor antagonist, a purine receptor antagonist, a vasopressin receptor antagonist, an opioid receptor antagonist, a leukotriene receptor antagonist, and an angiotensin receptor antagonist.

Details for Patent 10,369,219

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Jubilant Hollisterstier Llc	N/A	positive skin test control-histamine	Injection	103891	March 13, 1924	⤷ Start Trial	2035-08-04
Seqirus Inc.	AGRIFLU	influenza virus vaccine	Injection	125297	November 27, 2009	⤷ Start Trial	2035-08-04
Glaxosmithkline Biologicals	AREXVY	respiratory syncytial virus vaccine, adjuvanted	For Injection	125775	May 03, 2023	⤷ Start Trial	2035-08-04
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 10,369,219

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2016021599	⤷ Start Trial
United States of America	2019298825	⤷ Start Trial
United States of America	2017216429	⤷ Start Trial
United States of America	10471140	⤷ Start Trial
Japan	6893075	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.